Eli Lilly and Company

Phosplatin Therapeutics Inc.

Omeros Corporation

Linnaeus Therapeutics, Inc.

Wayne Douglas Luke

David W Hoard

Kerry John Hartauer

Robert Eugene Stratford, Jr

Gordon Nelson Arbuthnot

Brian Weston Dalder

Jennifer Lynn Gage

Thomas L Little, Jr

Neil S Cutshall

Karl Reineke

Elisabeth C A Brot

Christopher Natale

Tina Garyantes

Patrick T Mooney

Marco Jonas

Michael James McDermott

Steffen Jost

Elisabeth Ca Brot

Thomas L Little

Michael James Mcdermott

Ta-Sen Chou

Jennifer Leigh Nelson

Ekaterina Albert

Perry C Heath

Julie Kay Bush

Michael A Staszak

Christopher Scott Seadeek

Christopher William Doecke

Merlyn G Flom

Hua Zheng

Xufeng Sun

Preston Charles Conrad

Tyler D Ames

Jeffrey N Levy

Suba Iyer

Heidi Ann Sanderson

Elisabeth CA Brot

Patrick Mooney

Karl E Reineke

Robert E Stratford

The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.

Enantiomerically purified GPER agonist for use in treating disease states and conditions

Pharmaceutical compositions of phosphaplatin compounds, in particular buffered stable liquid formulations of pyrodach-2 ready for use in the treatment of various cancers, and methods of preparation are disclosed.

Phosphaplatin liquid formulations

The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the inhibition of PDE10.

Solid state forms of a PDE10 inhibitor

The present invention is directed to an improved process for the preparation of compounds of Formula (II) and Formula (III), which are useful in the inhibition of PDE10. In particular, the present invention is directed to an improved process for the preparation of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, which is useful in the inhibition of PDE10.

Processes and intermediates for the preparation of a PDE10 inhibitor

This application discloses novel methods and processes for preparation and purification of phosphaplatin compounds. The improvements of the synthetic methods and purification processes include, but are not limited to, efficient and reproducible large-scale preparation of these useful pharmaceutical agents in high quality and good yield.

Synthetic and purification methods for phosphaplatin compounds and uses thereof

Synthetic method for phosphaplatin compounds

This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

Benzothiophenes, formulations containing same, and methods

An improved process for the preparation of 4[(2-piperidin-1-yl)ethoxy]benzoic acid derivatives, comprising reacting a haloalkyl amine of formula (III) with a compound of formula (IV) in the presence of a hydrated inorganic base in an appropriate solvent.

Process for preparing benzoic acids

The present invention relates to a process for preparing a compound of formula (I): which includes cyclodehydrating a compound of formula (II): in the presence of an acid activated clay or acid activated zeolite catalyst and in the presence of a suitable solvent

Process for preparing 3-aryl-benzo{b} thiophenes

This invention provides compounds of formula Iand pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-&lsqb;2-(piperidin-1-yl)ethoxy&rsqb;phenoxy)-2-(4-methoxyphenyl)benzo&lsqb;b&rsqb;thiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT.

Crystalline form of 6-hydroxy-3-(4-&lsqb;2-(piperidin-1-yl)ethoxy&rsqb;phenoxy)-2-(4-methoxyphenyl)benzo&lsqb;b&rsqb; thiophene hydrochloride

Benzothiophenes formulations containing same and methods

The preparation of benzo[b]thiophenes by the acylation of alkoxy protected starting materials followed by demethylation using essentially odorless thiol compounds are provided herewith. Demethylation may be carried out in the same reaction vessel without isolation of the acylated, protected material.

Process for preparing benzo[b]thiophenes

Growing community of inventors

West Lafayette, IN, United States of America

Wayne Douglas Luke